Seeking Alpha

Tesaro +7%, BMO sees "significant opportunity" for rolapitant

  • Shares of Tesaro (TSRO +7%) are getting a boost from an upgrade by BMO Capital to Outperform from Perform along with a $10 PT hike to $46.
  • The firm cites meetings with management,  from which it came away seeing "a significant opportunity [...] for rolapitant within NCCN treatment guidelines" to the tune of peak sales of $400M.
  • Additional upside could come from "large contracts on rolapitant approval, IV development, and pipeline progress, particularly with PARP inhibitor niraparib."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector